Eric Schmidt
Stock Analyst
(n/a)
# 1,647
Out of 4,616 analysts
33
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics | Initiates: Overweight | n/a | $23.12 | - | 1 | Oct 8, 2024 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $41.06 | - | 3 | Sep 20, 2024 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $45.61 | +110.48% | 4 | Sep 18, 2024 | |
| INCY Incyte | Reiterates: Neutral | n/a | $66.17 | - | 4 | Sep 16, 2024 | |
| BLUE bluebird bio | Reiterates: Neutral | n/a | $0.51 | - | 2 | Sep 16, 2024 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $11.00 | - | 3 | Sep 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Overweight | n/a | $31.41 | - | 2 | Sep 9, 2024 | |
| BIIB Biogen | Reiterates: Overweight | $292 | $182.84 | +59.70% | 3 | Sep 9, 2024 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $10.52 | - | 2 | Aug 19, 2024 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $45.15 | - | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.14 | - | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $3.19 | - | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $454.73 | -18.63% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.22 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.11 | - | 1 | May 30, 2017 |
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: n/a
Current: $23.12
Upside: -
Agios Pharmaceuticals
Sep 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $41.06
Upside: -
Avidity Biosciences
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $45.61
Upside: +110.48%
Incyte
Sep 16, 2024
Reiterates: Neutral
Price Target: n/a
Current: $66.17
Upside: -
bluebird bio
Sep 16, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.51
Upside: -
Immatics
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.00
Upside: -
Immunocore Holdings
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.41
Upside: -
Biogen
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $182.84
Upside: +59.70%
Alumis
Aug 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.52
Upside: -
CRISPR Therapeutics AG
Aug 8, 2024
Reiterates: Neutral
Price Target: n/a
Current: $45.15
Upside: -
Jul 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.14
Upside: -
May 30, 2024
Initiates: Overweight
Price Target: n/a
Current: $3.19
Upside: -
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $454.73
Upside: -18.63%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.22
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.11
Upside: -